Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Tidal Investments LLC

Tidal Investments LLC decreased its holdings in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 21.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 500,000 shares of the biopharmaceutical company's stock after selling 133,411 shares during the quarter. Tidal Investments LLC owned about 0.31% of Novavax worth $6,315,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NVAX. Banque Cantonale Vaudoise lifted its stake in shares of Novavax by 500.0% in the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 2,500 shares during the period. Amalgamated Bank increased its holdings in Novavax by 26.9% in the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company's stock valued at $62,000 after buying an additional 1,036 shares in the last quarter. Signaturefd LLC lifted its position in shares of Novavax by 214.5% during the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company's stock valued at $72,000 after acquiring an additional 3,874 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Novavax by 38.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock worth $77,000 after acquiring an additional 1,598 shares in the last quarter. Finally, Midland Wealth Advisors LLC acquired a new stake in shares of Novavax in the 2nd quarter worth approximately $152,000. Institutional investors and hedge funds own 53.04% of the company's stock.

Analyst Upgrades and Downgrades

NVAX has been the topic of a number of research analyst reports. B. Riley reiterated a "buy" rating and set a $26.00 target price (up from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Jefferies Financial Group decreased their price objective on shares of Novavax from $31.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, October 16th. Finally, HC Wainwright reissued a "buy" rating and issued a $19.00 price objective on shares of Novavax in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $17.83.

Novavax Trading Up 1.0 %

Shares of NASDAQ:NVAX traded up $0.09 on Friday, hitting $9.11. The company had a trading volume of 3,221,919 shares, compared to its average volume of 9,325,702. The company has a market cap of $1.46 billion, a PE ratio of -4.03 and a beta of 2.02. Novavax, Inc. has a 52-week low of $3.53 and a 52-week high of $23.86. The business has a 50 day moving average of $9.53 and a 200 day moving average of $12.17.

Novavax (NASDAQ:NVAX - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to analysts' expectations of $65.80 million. Novavax's revenue for the quarter was down 54.8% on a year-over-year basis. During the same quarter last year, the company posted ($1.26) earnings per share. As a group, equities analysts predict that Novavax, Inc. will post -1.44 EPS for the current year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.